^
Association details:
| Biomarker: | TPM3-NTRK1 fusion + ALK L1196M |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Vitrakvi (larotrectinib) (TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
4120 / 4 - Acquired TPM3-NTRK1 fusion resistant to larotrectinib in a non-small cell lung cancer with EML4-ALK fusion progressed on lorlatinib
Published date:
03/09/2022
Excerpt:
A 48-year-old male with stage IV adenocarcinoma of lung...Repeat ctDNA NGS assay revealed new TPM3-NTRK1 fusion (VAF 0.2%) and ALK L1196M (VAF 2.8%), and a decision was made to add larotrectinib 100 mg daily. The 6-week follow-up MRI brain showed new parenchymal brain metastases.
